Overcoming Obstacles to Drug Repositioning in Japan
Open Access
- 11 October 2017
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 8, 729
Abstract
Drug repositioning (DR) is the process of identifying new indications for existing drugs. DR usually focuses on drugs that have cleared phase-I safety trials but has yet to show efficacy for the intended indication. Therefore, DR can probably skip the preclinical and phase-I study, which can reduce the cost throughout drug development. However, the expensive phase-II/III trials are required to establish efficacy. The obstacles to DR include identification of new indications with a high success rate in clinical studies, obtaining funding for clinical studies, patent protection, and approval systems. To tackle these obstacles, various approaches have been applied to DR worldwide. In this perspective, we provide representative examples of DR and discuss the ongoing efforts to overcome obstacles to DR in Japan.Keywords
This publication has 45 references indexed in Scilit:
- High-Performance Prediction of Human Estrogen Receptor Agonists Based on Chemical StructuresMolecules, 2017
- The ChEMBL database in 2017Nucleic Acids Research, 2016
- Deep Learning Applications for Predicting Pharmacological Properties of Drugs and Drug Repurposing Using Transcriptomic DataMolecular Pharmaceutics, 2016
- Creating New Economic Incentives for Repurposing Generic Drugs for Unsolved Diseases Using Social FinanceASSAY and Drug Development Technologies, 2015
- LINCS Canvas Browser: interactive web app to query, browse and interrogate LINCS L1000 gene expression signaturesNucleic Acids Research, 2014
- GWAS and drug targetsBMC Genomics, 2014
- Progressive Approval: A Proposal for a New Regulatory Pathway for Regenerative MedicineStem Cells Translational Medicine, 2014
- Analysis of 10 years drug lifecycle management (LCM) activities in the Japanese marketDrug Discovery Today, 2013
- From depression to neurodegeneration and heart failure: re-examining the potential of MAO inhibitorsExpert Review of Clinical Pharmacology, 2012
- SuperTarget and Matador: resources for exploring drug-target relationshipsNucleic Acids Research, 2007